Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07051031 · ClinicalTrials.gov registry record · Phase 4
COVID-19 Reactogenicity
A Phase 4 study of COVID-19, sponsored by Marcel Curlin.
- Active
- Registry status
- Phase 4
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT07051031 is a Phase 4 study of COVID-19 that is active but no longer recruiting, run by Marcel Curlin. The registered enrollment target is 1,000 participants, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07051031, a Phase 4 study of COVID-19, is active but no longer recruiting, sponsored by Marcel Curlin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
Conditions Studied
Interventions
- DRUG Nuvaxovid (NVX-CoV2705)
- DRUG mNEXSPIKE mRNA-1283
Study Locations (1)
Oregon
- Oregon Health and Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-06-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07051031
The ClinicalTrials.gov registry entry for NCT07051031 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The listed sponsor is Marcel Curlin, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Nuvaxovid (NVX-CoV2705) is the first listed.
NCT07051031 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT07051031 about?
NCT07051031 is a clinical study titled "COVID-19 Reactogenicity". The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
What is the current status of trial NCT07051031?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2025-10-01. Estimated completion is 2026-06-14.
What conditions does trial NCT07051031 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07051031?
The interventions under investigation include: Nuvaxovid (NVX-CoV2705) (DRUG), mNEXSPIKE mRNA-1283 (DRUG).
Who is sponsoring clinical trial NCT07051031?
This trial is sponsored by Marcel Curlin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07051031 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.